| (Values in U.S. Thousands) | Jun, 2022 | Mar, 2022 | Dec, 2021 | Sep, 2021 | Jun, 2021 |
| Sales | 20,570 | 17,400 | 23,990 | 23,670 | 21,760 |
| Sales Growth | +18.22% | -27.47% | +1.35% | +8.78% | +54.88% |
| Net Income | -35,120 | -27,510 | -26,420 | -20,020 | -14,220 |
| Net Income Growth | -27.66% | -4.13% | -31.97% | -40.79% | +17.37% |
Genetron Holdings Ltd ADR (GTH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Genetron Holdings Limited provides precision oncology platform principally in China. It specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company's product and service portfolio cover the full-cycle of cancer care from early screening, to diagnosis and treatment recommendations, to continuous monitoring and continuous care. Genetron Holdings Limited is based in BEIJING, China.
Fiscal Year End Date: 12/31